Overexpression of ERα is a hallmark of estrogen receptor-positive (ER+) breast cancers, making it a crucial target for endocrine therapy using selective estrogen receptor modulators (SERMs) like tamoxifen. This evidence concerns the gene ESR1 and breast cancer.